AKBA - Akebia Therapeutics Inc Stock Price, Fair Value and News

$1.83+0.04 (+2.23%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AKBA Price Action

Last 7 days

-1.1%

Last 30 days

2.2%

Last 90 days

33.6%

Trailing 12 Months

52.5%

AKBA RSI Chart

AKBA Valuation

Market Cap

399.3M

Price/Earnings (Trailing)

-8.68

Price/Sales (Trailing)

2.35

EV/EBITDA

-9.08

Price/Free Cashflow

-10.6

AKBA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AKBA Fundamentals

AKBA Revenue

Revenue (TTM)

169.9M

Rev. Growth (Yr)

-10.98%

Rev. Growth (Qtr)

-14.25%

AKBA Earnings

Earnings (TTM)

-46.0M

Earnings Growth (Yr)

-38.3%

Earnings Growth (Qtr)

-133.5%

AKBA Profitability

Operating Margin

63.81%

EBT Margin

-27.07%

Return on Equity

91.25%

Return on Assets

-22.2%

Free Cashflow Yield

-9.44%

AKBA Investor Care

Shares Dilution (1Y)

15.81%

Diluted EPS (TTM)

-0.22

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	187.2M	174.5M	169.9M	0
2023	271.0M	200.6M	194.0M	194.6M
2022	221.0M	294.9M	294.8M	292.7M
2021	236.0M	198.7M	232.5M	211.7M
2020	350.8M	340.2M	263.2M	272.1M
2019	234.5M	286.5M	325.3M	335.0M
2018	203.0M	223.3M	235.2M	207.7M
2017	22.5M	51.0M	92.2M	178.0M
2016	0	0	0	1.8M
2015	612.2K	525.2K	410.2K	0
2014	962.4K	875.0K	787.6K	700.2K
2013	0	0	1.5M	1.0M
2012	0	0	0	2.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. John P. Butler MBA
WEBSITE	akebia.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	204

Akebia Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Akebia Therapeutics Inc? What does AKBA stand for in stocks?

AKBA is the stock ticker symbol of Akebia Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akebia Therapeutics Inc (AKBA)?

As of Fri Dec 20 2024, market cap of Akebia Therapeutics Inc is 399.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKBA stock?

You can check AKBA's fair value in chart for subscribers.

Is Akebia Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AKBA is over valued or under valued. Whether Akebia Therapeutics Inc is cheap or expensive depends on the assumptions which impact Akebia Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKBA.

What is Akebia Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, AKBA's PE ratio (Price to Earnings) is -8.68 and Price to Sales (PS) ratio is 2.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKBA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Akebia Therapeutics Inc's stock?

In the past 10 years, Akebia Therapeutics Inc has provided -0.168 (multiply by 100 for percentage) rate of return.